Stock Track | Moderna Soars 5.35% in Pre-Market After Q1 Revenue and EPS Beat Estimates on Strong International Vaccine Sales

Stock Track18:39

Moderna, Inc. (MRNA) experienced a significant pre-market surge of 5.35%, following the release of its first-quarter financial results which exceeded analyst expectations.

The vaccine maker reported quarterly revenue of $389 million, substantially above the consensus estimate of approximately $228 million. This growth was primarily driven by stronger-than-anticipated sales of its COVID-19 vaccine in international markets, which accounted for $311 million of the total revenue. The company also reported a smaller-than-expected loss per share of $3.40, beating the estimated loss of $3.96.

Moderna reiterated its financial outlook for 2026, forecasting revenue growth of up to 10% compared to the previous year. The positive results and reaffirmed guidance, coupled with progress in its pipeline including a seasonal flu vaccine awaiting regulatory decision, contributed to the bullish investor sentiment in the pre-market session.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1173325781?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-01 18:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173325781","market":"nz","top_or_hot":-1,"title":"Stock Track | Moderna Soars 5.35% in Pre-Market After Q1 Revenue and EPS Beat Estimates on Strong International Vaccine Sales","media":"Stock Track","content":"<p>Moderna, Inc. (MRNA) experienced a significant pre-market surge of 5.35%, following the release of its first-quarter financial results which exceeded analyst expectations.</p><p>The vaccine maker reported quarterly revenue of $389 million, substantially above the consensus estimate of approximately $228 million. This growth was primarily driven by stronger-than-anticipated sales of its COVID-19 vaccine in international markets, which accounted for $311 million of the total revenue. The company also reported a smaller-than-expected loss per share of $3.40, beating the estimated loss of $3.96.</p><p>Moderna reiterated its financial outlook for 2026, forecasting revenue growth of up to 10% compared to the previous year. The positive results and reaffirmed guidance, coupled with progress in its pipeline including a seasonal flu vaccine awaiting regulatory decision, contributed to the bullish investor sentiment in the pre-market session.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Moderna Soars 5.35% in Pre-Market After Q1 Revenue and EPS Beat Estimates on Strong International Vaccine Sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Moderna Soars 5.35% in Pre-Market After Q1 Revenue and EPS Beat Estimates on Strong International Vaccine Sales\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-01 18:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Moderna, Inc. (MRNA) experienced a significant pre-market surge of 5.35%, following the release of its first-quarter financial results which exceeded analyst expectations.</p><p>The vaccine maker reported quarterly revenue of $389 million, substantially above the consensus estimate of approximately $228 million. This growth was primarily driven by stronger-than-anticipated sales of its COVID-19 vaccine in international markets, which accounted for $311 million of the total revenue. The company also reported a smaller-than-expected loss per share of $3.40, beating the estimated loss of $3.96.</p><p>Moderna reiterated its financial outlook for 2026, forecasting revenue growth of up to 10% compared to the previous year. The positive results and reaffirmed guidance, coupled with progress in its pipeline including a seasonal flu vaccine awaiting regulatory decision, contributed to the bullish investor sentiment in the pre-market session.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"","article_id":"1173325781","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173325781","pubTimestamp":1777631964,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Moderna, Inc. (MRNA) experienced a significant pre-market surge of 5.35%, following the release of its first-quarter financial results which exceeded analyst expectations.The vaccine maker reported...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"个股追踪|Moderna盘前大涨5.35%，Q1营收和EPS超预期因国际疫苗销售强劲","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":1},"content_text":"Moderna, Inc. (MRNA) experienced a significant pre-market surge of 5.35%, following the release of its first-quarter financial results which exceeded analyst expectations.The vaccine maker reported quarterly revenue of $389 million, substantially above the consensus estimate of approximately $228 million. This growth was primarily driven by stronger-than-anticipated sales of its COVID-19 vaccine in international markets, which accounted for $311 million of the total revenue. The company also reported a smaller-than-expected loss per share of $3.40, beating the estimated loss of $3.96.Moderna reiterated its financial outlook for 2026, forecasting revenue growth of up to 10% compared to the previous year. The positive results and reaffirmed guidance, coupled with progress in its pipeline including a seasonal flu vaccine awaiting regulatory decision, contributed to the bullish investor sentiment in the pre-market session.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1173325781","isCrawlerRequest":true}